Visão geral da empresa
A biopharmaceutical enterprise, Rein Therapeutics Inc. is dedicated to the development of therapeutic medicines aimed at addressing unmet medical needs specifically within orphan pulmonary and fibrosis indications in the United States. The company operates within the Healthcare sector and functions specifically in the Biotechnology industry, a classification that implies a focus on innovative drug discovery and clinical development rather than established commercial manufacturing. Rein Therapeutics Inc. currently holds a market capitalization of $33.93M, operates with an annual revenue status of N/A, and has an employee count listed as N/A. The company's market capitalization of $33.93M indicates a small-cap positioning within the biotechnology landscape, suggesting a higher risk profile and potential for volatility compared to large-cap peers, while the absence of specific revenue and employee data points to a pre-revenue or early-stage operational model where capital is primarily allocated toward research and development rather than commercial sales infrastructure.
Saúde financeira
The financial statements for Rein Therapeutics Inc. report a Revenue (TTM) of N/A, a Net Income (TTM) of $-49,871,000, and an EBITDA of $-21,930,000. The significant gap between the negligible or undefined revenue and the substantial negative net income of $-49,871,000 reveals a cost structure heavily weighted toward research, development, and operational overheads typical of early-stage biotechnology firms that have not yet generated significant commercial sales. The company reports a Free Cash Flow of $-11,369,875, indicating a net cash outflow that limits immediate financial flexibility but is characteristic of companies in the investment phase seeking to advance clinical trials for their lead product candidate. All three margins—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, which indicates that the company has not yet achieved profitability and is currently burning cash to fund its pipeline without generating sufficient gross profit to cover operating expenses. In terms of leverage, the company holds Cash of $3.21M and carries $0 in Debt, a combination that suggests a conservative balance sheet free from interest obligations, though the lack of cash reserves relative to burn rate poses liquidity risks. The Debt to Equity ratio is listed as N/A due to the absence of equity in the denominator or debt, but the zero debt figure confirms no leverage. The Current Ratio stands at 0.70, which indicates that current assets are insufficient to cover current liabilities, signaling potential short-term liquidity constraints that the company must address through fundraising or cash conservation measures. Furthermore, the Return on Equity is -139.9% and the Return on Assets is -31.7%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a common but critical indicator of financial stress in pre-commercial biotech entities.
Avaliação de valorização
The trailing P/E Ratio (TTM) and Forward P/E are both listed as N/A, implying that the absence of positive earnings makes traditional earnings-based valuation multiples inapplicable, as the difference between them cannot be analyzed in the context of an earnings trajectory for a non-profitable entity. The Price to Book ratio is -1.19, a negative figure that indicates the market values the company at a discount to its book value, reflecting the high risk and lack of tangible asset backing relative to its equity, rather than a standard market premium over book value. Alternative valuation metrics such as the Price to Sales ratio of N/A and the EV/EBITDA of -3.45 suggest that investors are valuing the firm based on pipeline potential and clinical milestones rather than current financial performance, with the negative EV/EBITDA highlighting the cash-burning nature of the business model. The 52-Week High is $2.40 and the 52-Week Low is $1.02; without a specific current price provided in the facts to calculate an exact percentage, the trading range indicates significant price discovery volatility typical of micro-cap biotechnology stocks. The Beta is 1.40, which means the stock's price volatility is expected to be 40% higher than the broader market, exposing holders to amplified swings in market sentiment and sector-specific news regarding clinical trial outcomes.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue, though the negative net income of $-49,871,000 implies that earnings are currently negative while revenue generation has not yet materialized to support positive growth rates. Rein Therapeutics Inc. does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the company reinvests all available resources, including its limited cash of $3.21M, into research and development efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current commercial growth metrics and dividend income, relying entirely on future clinical trial successes to potentially transform the company's financial trajectory from a cash-burning entity to a revenue-generating one.